qpatch automated patch-clamp platform (Sophion Bioscience)
Structured Review

Qpatch Automated Patch Clamp Platform, supplied by Sophion Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/automated+patch-clamp+platform+qpatch/qpatch+16+automated+electrophysiology+platform/pmc11808707-32-55-59
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Analgesia and peripheral c-fiber modulation by selective Na v 1.8 inhibition in rhesus"
Article Title: Analgesia and peripheral c-fiber modulation by selective Na v 1.8 inhibition in rhesus
Journal: Pain
doi: 10.1097/j.pain.0000000000003404
Figure Legend Snippet: Na v channel compound profile assessed on the Qube or Qpatch*. Ten-point titrations in the Qube automated patch-clamp assay determined MSD199 to be a potent and selective compound (IC 50 = 4.7 ± 0.8 nM, mean ± SD). MSD199 potency was too weak to calculate for all other Na v isoforms except Na v 1.4, which was 1781-fold shifted to 8370 nM mean IC 50 ± 1429.
Techniques Used: Patch Clamp
Related Articles
other:Article Title: Synthesis and bioevaluation of diaryl urea derivatives as potential antitumor agents for the treatment of human colorectal cancer. Article Snippet: The development of inhibitors targeting the PI3K-Akt-mTOR signaling pathway has been greatly hindered by the on-target AEs, such as hyperglycemia and hepatotoxicities.. In this study, a series of diaryl urea derivatives has been designed and synthesized based on clinical candidate gedatolisib (6aa), and most of the newly synthesized derivatives showed kinase inhibitory and antiproliferative activities within nanomolar and submicromolar level, respectively.. The terminal L-prolineamide substituted derivative 6 ab showed 8.6-fold more potent PI3Ka inhibitory activity (0.7 nM) and 4.6-fold more potent antiproliferative effect against HCT116 cell lines (0.11 mM) compared with control 6aa. |